Free tool
FAERS Monitor: Dojolvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213687 or its brand name (Dojolvi, Triheptanoin). Reports on generic versions are filed under their own applications.
Reports
554
Serious
350
63% of reports
Hospitalization
268
Death reported
69
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting88
- diarrhoea77
- rhabdomyolysis56
- off label use53
- abdominal pain upper44
- abdominal discomfort36
- blood creatine phosphokinase increased35
- death33
- nausea29
- illness25
- gastrointestinal disorder24
- hospitalisation24
- abdominal pain21
- metabolic disorder20
- product dose omission issue17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 27 |
| 2021 | 90 |
| 2022 | 117 |
| 2023 | 114 |
| 2024 | 99 |
| 2025 | 67 |
| 2026 | 40 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,605 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metabolic disorderSignal | 20 | 131.2 | 85.3 | 2,448 |
| rhabdomyolysisSignal | 56 | 51.1 | 39.8 | 2,700 |
| blood creatine phosphokinase increasedSignal | 35 | 46.2 | 33.5 | 1,504 |
| gastrointestinal disorderSignal | 24 | 10.2 | 6.9 | 190 |
| illnessSignal | 25 | 9.2 | 6.3 | 176 |
| abdominal discomfortSignal | 36 | 8.1 | 5.9 | 220 |
| abdominal pain upperSignal | 44 | 8.1 | 6.1 | 270 |
| vomitingSignal | 88 | 7.1 | 5.9 | 466 |
| hospitalisationSignal | 24 | 5.9 | 4.0 | 94 |
| diarrhoeaSignal | 77 | 4.5 | 3.7 | 215 |
| abdominal painSignal | 21 | 3.4 | 2.3 | 34 |
| off label useSignal | 53 | 2.3 | 1.8 | 39 |
| product dose omission issueSignal | 17 | 2.2 | 1.4 | 10 |
| death | 33 | 1.5 | 1.0 | 4 |
| nausea | 29 | 1.4 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.